- Funding to Date*
In the last few years, aptamers linked to CRISPR have brought programmable logic to drug design. However, the logic is primitive – once turned on, CRISPR remains on. Wayfinder is working on RNA-biosensors so that drugs can continuously sense their microenvironment, and turn modalities like CRISPR both on and off in response to what they are sensing.
And they do it way faster than anyone else in the world. Wayfinder is WAY faster.
A spinout from the Center for Synthetic Biology at the University of Washington, Wayfinder has already done 8 biosensors and is engaging multiple ecosystem partners.